Table 1.
FDA approved ADCs and their characteristics.
| Trade Name | Generic Name | Conjugate | Average DAR | Indication | Target |
|---|---|---|---|---|---|
| MYLOTARG | Gemtuzumab ozogamicin | Calicheamicin | 2–3 | Hematological | CD33 |
| ADCETRIS | brentuximab vedotin | Monomethyl auristatin E (MMAE) | 4 | Hematological | CD30 |
| BESPONSA | Inotuzumab ozogamicin | Calicheamicin | 6 | Hematological | CD22 |
| POLIVY | Polatuzumab vedotin | Monomethyl auristatin E (MMAE) | 3.5 | Hematological | CD79b |
| KADCYLA | Trastuzumab emtansine | Myatansinoid (DM1) | 3.5 | Solid tumor | HER2 |
| ENHERTU | Trastuzumab deruxtecan | Deruxtecan (Dxd) | 7–8 | Solid tumor | HER2 |
| PADCEV | Enfortumab vedotin | Monomethyl auristatin E (MMAE) | 3.8 | Solid tumor | Nectin-4 |
| TRODELVY | Sacituzumab govitecan | Govitecan SN-38 | 7.6 | Solid tumor | Trop-2 |
| BLENREP | Belantamab mafodotin | microtubule inhibitor MMAF | 4 | Myeloma | BCMA |
Taken and modified from reference [11].